Autochthonous T cells to the rescue: IL-10 directly activates tumor-resident CD8+ T cells

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1637-1639

  Emmerich, Jan ^a   Mumm, John B ^b   Oft, Martin ^b  

^a TriMod Therapeutics   (Ireland)

^b Targenics   (United States)

Author keywords

Autochthon; CD8+ T cell; Cytotoxicity; IL 10; Immunotherapy; TIL; Tumor infiltrating T cells; Tumor resident T cell

Indexed keywords

CYTOKINE; GRANZYME B; INTERLEUKIN 10; STAT1 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRACKING; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NOTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR REJECTION;

EID: 84886944027     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21683     Document Type: Note

References (10)

1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; http://dx.doi.org/10.1038/nature10673; PMID:22193102.
2. Fridman WH, Pagés F, Sautés-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; http://dx.doi.org/10.1038/nrc3245; PMID:22419253.
3. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599-613; http://dx.doi.org/10.1093/jnci/djs033; PMID:22395641.
4. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765; PMID:11244051; http://dx.doi.org/10.1146/annurev.immunol.19.1.683.
5. Fujii S, Shimizu K, Shimizu T, Lotze MT. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 2001; 98:2143-51; PMID:11568001; http://dx.doi.org/10.1182/blood.V98.7.2143.
6. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, et al. IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell 2011; 20:781- 96; PMID:22172723; http://dx.doi.org/10.1016/j.ccr.2011.11.003.
7. Emmerich J, Mumm JB, Chan IH, Laface D, Truong H, McClanahan T, et al. IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs. Cancer Res 2012; 72:3570-81; http://dx.doi.org/10.1158/0008-5472.CAN-12-0721; PMID:22581824.
8. Dorsey R, Kundu N, Yang Q, Tannenbaum CS, Sun H, Hamilton TA, et al. Immunotherapy with interleukin- 10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res 2002; 62:2606-10; PMID:11980656.
9. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 2000; 165:2783-9; PMID:10946310.
10. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002; 50:191-5; PMID:11788558; http://dx.doi.org/10.1136/gut.50.2.191.